Anthera Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANTH)

$2.40 +0.04 (+1.69 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$2.40
Today's Range$2.17 - $2.57
52-Week Range$1.20 - $6.24
Volume5.04 million shs
Average Volume2.78 million shs
Market Capitalization$32.69 million
P/E Ratio-0.44
Dividend YieldN/A
Beta2.67

About Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals logoAnthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Receive ANTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ANTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANTH
CUSIPN/A
Phone510-856-5600

Debt

Debt-to-Equity RatioN/A
Current Ratio1.97%
Quick Ratio1.97%

Price-To-Earnings

Trailing P/E Ratio-0.439559634506164
Forward P/E Ratio-0.78
P/E GrowthN/A

Sales & Book Value

Annual Sales$140,000.00
Price / Sales237.43
Cash FlowN/A
Price / CashN/A
Book Value$0.67 per share
Price / Book3.58

Profitability

Trailing EPS($5.46)
Net Income$-55,520,000.00
Net MarginsN/A
Return on Equity-1,497.08%
Return on Assets-224.18%

Miscellaneous

Employees33
Outstanding Shares13,850,000

Anthera Pharmaceuticals (NASDAQ:ANTH) Frequently Asked Questions

What is Anthera Pharmaceuticals' stock symbol?

Anthera Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANTH."

When did Anthera Pharmaceuticals' stock split? How did Anthera Pharmaceuticals' stock split work?

Anthera Pharmaceuticals shares reverse split before market open on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of Anthera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were Anthera Pharmaceuticals' earnings last quarter?

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) released its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.32. During the same period last year, the business earned ($4.85) earnings per share. View Anthera Pharmaceuticals' Earnings History.

When will Anthera Pharmaceuticals make its next earnings announcement?

Anthera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Anthera Pharmaceuticals.

Where is Anthera Pharmaceuticals' stock going? Where will Anthera Pharmaceuticals' stock price be in 2018?

3 analysts have issued 12-month target prices for Anthera Pharmaceuticals' shares. Their predictions range from $1.75 to $10.00. On average, they anticipate Anthera Pharmaceuticals' stock price to reach $4.92 in the next twelve months. View Analyst Ratings for Anthera Pharmaceuticals.

Who are some of Anthera Pharmaceuticals' key competitors?

Who are Anthera Pharmaceuticals' key executives?

Anthera Pharmaceuticals' management team includes the folowing people:

  • Paul F. Truex, Executive Chairman of the Board
  • Craig Thompson, President, Chief Executive Officer, Chief Operating Officer, Director (Age 50)
  • May Liu, Senior Vice President - Finance and Administration, Principal Accounting Officer (Age 39)
  • Patrick M. Murphy, Senior Vice President - Manufacturing (Age 60)
  • William R. Shanahan Jr. M.D. J.D., Chief Medical Officer (Age 68)
  • Brent Furse, Director (Age 47)
  • Christopher S. Henney Ph.D., Independent Director (Age 76)
  • Brian R. Mueller, Independent Director (Age 43)
  • Philip T Sager, Independent Director (Age 59)
  • David E. Thompson, Independent Director (Age 67)

Who owns Anthera Pharmaceuticals stock?

Anthera Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include 683 CAPITAL MANAGEMENT, LLC Total Shares: 1,440,000 (6.70%), BVF Inc. IL (8.78%), Armistice Capital LLC (5.55%), 683 Capital Management LLC (2.00%) and Millennium Management LLC (0.49%). Company insiders that own Anthera Pharmaceuticals stock include John Craig Thompson and Paul F Truex. View Institutional Ownership Trends for Anthera Pharmaceuticals.

Who sold Anthera Pharmaceuticals stock? Who is selling Anthera Pharmaceuticals stock?

Anthera Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Anthera Pharmaceuticals.

Who bought Anthera Pharmaceuticals stock? Who is buying Anthera Pharmaceuticals stock?

Anthera Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Armistice Capital LLC, 683 Capital Management LLC and BVF Inc. IL. Company insiders that have bought Anthera Pharmaceuticals stock in the last two years include John Craig Thompson and Paul F Truex. View Insider Buying and Selling for Anthera Pharmaceuticals.

How do I buy Anthera Pharmaceuticals stock?

Shares of Anthera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anthera Pharmaceuticals' stock price today?

One share of Anthera Pharmaceuticals stock can currently be purchased for approximately $2.40.

How big of a company is Anthera Pharmaceuticals?

Anthera Pharmaceuticals has a market capitalization of $32.69 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-55,520,000.00 in net income (profit) each year or ($5.46) on an earnings per share basis. Anthera Pharmaceuticals employs 33 workers across the globe.

How can I contact Anthera Pharmaceuticals?

Anthera Pharmaceuticals' mailing address is 25801 INDUSTRIAL BOULEVARD SUITE B, HAYWARD CA, 94545. The biopharmaceutical company can be reached via phone at 510-856-5600.


MarketBeat Community Rating for Anthera Pharmaceuticals (ANTH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  430
MarketBeat's community ratings are surveys of what our community members think about Anthera Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Anthera Pharmaceuticals (NASDAQ:ANTH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.672.502.402.40
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.92$2.38$5.89$11.14
Price Target Upside: 190.93% upside79.92% upside346.02% upside776.97% upside

Anthera Pharmaceuticals (NASDAQ:ANTH) Consensus Price Target History

Price Target History for Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals (NASDAQ:ANTH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/21/2018Roth CapitalInitiated CoverageBuy -> Buy$10.00 -> $10.00HighView Rating Details
9/19/2017HC WainwrightReiterated RatingBuy$3.00MediumView Rating Details
8/11/2017Jefferies GroupReiterated RatingHold$2.25 -> $1.75LowView Rating Details
12/29/2016Piper Jaffray CompaniesLower Price TargetOverweight$56.00 -> $10.80N/AView Rating Details
12/29/2016CitigroupDowngradeBuy -> NeutralN/AView Rating Details
12/28/2016SunTrust BanksDowngradeBuy -> Hold$48.00 -> $8.00N/AView Rating Details
6/20/2016FBR & CoReiterated RatingHoldN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Anthera Pharmaceuticals (NASDAQ:ANTH) Earnings History and Estimates Chart

Earnings by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals (NASDAQ ANTH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.82)N/AView Earnings Details
11/6/2017Q3 2017($0.90)($0.58)ViewN/AView Earnings Details
8/9/2017Q2 2017($1.09)$0.03ViewN/AView Earnings Details
5/10/2017Q1 2017($1.47)($2.03)ViewN/AView Earnings Details
2/27/2017Q4 2016($3.25)($2.88)$0.10 millionViewN/AView Earnings Details
11/4/2016Q3($3.04)($4.88)$0.18 millionViewN/AView Earnings Details
8/9/2016Q2($2.48)($2.80)$0.15 millionViewN/AView Earnings Details
5/9/2016Q1($2.24)($2.32)$0.15 millionViewN/AView Earnings Details
3/10/2016Q4($2.24)($1.44)$0.31 million$1.92 millionViewN/AView Earnings Details
11/6/2015Q315($2.08)($2.32)$0.31 million$0.73 millionViewN/AView Earnings Details
8/10/2015Q2($2.24)($2.00)$0.29 millionViewN/AView Earnings Details
5/11/2015Q115($2.48)($2.24)$0.25 millionViewN/AView Earnings Details
3/16/2015Q4 2014($2.64)($2.56)ViewN/AView Earnings Details
11/14/2014Q3 2014($2.88)($2.48)ViewN/AView Earnings Details
7/28/2014Q2 2014($3.92)($2.72)ViewN/AView Earnings Details
5/13/2014Q114($4.48)($3.12)ViewN/AView Earnings Details
3/12/2014($3.76)($3.84)ViewN/AView Earnings Details
10/29/2013Q3 2013($5.20)($2.40)ViewN/AView Earnings Details
7/30/2013Q2 2013($4.80)($3.28)ViewN/AView Earnings Details
5/13/2013Q1 2013($4.48)($3.84)ViewN/AView Earnings Details
3/26/2013Q412($1.20)($0.88)ViewN/AView Earnings Details
10/24/2012Q3 2012($10.24)($10.88)ViewN/AView Earnings Details
8/7/2012Q2 2012($22.40)($27.39)ViewN/AView Earnings Details
5/3/2012Q1 2012($35.20)($32.64)ViewN/AView Earnings Details
2/21/2012Q4 2011($38.40)($45.63)ViewN/AView Earnings Details
11/1/2011Q3 2011($34.56)($38.34)ViewN/AView Earnings Details
7/29/2011Q2 2011($33.92)($42.50)ViewN/AView Earnings Details
5/3/2011Q1 2011($23.68)($36.10)ViewN/AView Earnings Details
2/23/2011Q4 2010($19.84)($25.41)ViewN/AView Earnings Details
11/2/2010Q3 2010($30.08)($23.23)ViewN/AView Earnings Details
8/4/2010Q2 2010($16.00)($22.85)ViewN/AView Earnings Details
5/6/2010Q1 2010($12.80)($53.25)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Anthera Pharmaceuticals (NASDAQ:ANTH) Earnings Estimates

2018 EPS Consensus Estimate: ($2.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.68)($0.68)($0.68)
Q2 20181($0.68)($0.68)($0.68)
Q3 20181($0.67)($0.67)($0.67)
Q4 20181($0.65)($0.65)($0.65)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Anthera Pharmaceuticals (NASDAQ:ANTH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Anthera Pharmaceuticals (NASDAQ ANTH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.08%
Institutional Ownership Percentage: 16.44%
Insider Trades by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)
Institutional Ownership by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals (NASDAQ ANTH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/20/2017John Craig ThompsonCEOBuy8,550$1.32$11,286.0019,848View SEC Filing  
9/7/2017John Craig ThompsonCEOBuy10,400$1.43$14,872.0011,298View SEC Filing  
9/7/2017Paul F TruexDirectorBuy5,000$1.34$6,700.00View SEC Filing  
11/13/2015Colin HislopinsiderSell12,500$5.31$66,375.0019,147View SEC Filing  
11/11/2015Colin HislopInsiderSell5,000$5.38$26,900.0019,147View SEC Filing  
10/12/2015Debra OdinkCTOSell1,205$6.15$7,410.757,896View SEC Filing  
6/24/2013David E ThompsonDirectorBuy12,500$0.53$6,625.00View SEC Filing  
5/31/2013Bogdan DziurzynskiDirectorBuy1,250$0.59$737.50View SEC Filing  
1/30/2013Orbimed Advisors LlcDirectorBuy712,500$0.66$470,250.00View SEC Filing  
1/25/2013Orbimed Advisors LlcDirectorBuy220,250$0.65$143,162.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Anthera Pharmaceuticals (NASDAQ ANTH) News Headlines

Source:
DateHeadline
Technical Perspectives on Biotech Stocks -- AnaptysBio, Anthera Pharma, Aralez Pharma, and Aratana Therapeutics - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- AnaptysBio, Anthera Pharma, Aralez Pharma, and Aratana Therapeutics - PR Newswire (press release)
www.prnewswire.com - February 23 at 8:21 AM
Anthera Pharmaceuticals (ANTH) Research Coverage Started at Roth CapitalAnthera Pharmaceuticals (ANTH) Research Coverage Started at Roth Capital
www.americanbankingnews.com - February 21 at 11:46 PM
Zacks Investment Research Downgrades Anthera Pharmaceuticals (ANTH) to HoldZacks Investment Research Downgrades Anthera Pharmaceuticals (ANTH) to Hold
www.americanbankingnews.com - February 21 at 4:58 PM
Anthera Pharmaceuticals Inc (ANTH) Receives Average Recommendation of "Hold" from BrokeragesAnthera Pharmaceuticals Inc (ANTH) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 21 at 11:18 AM
Anthera Pharmaceuticals (ANTH) Upgraded by Zacks Investment Research to "Buy"Anthera Pharmaceuticals (ANTH) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - February 20 at 5:08 PM
Anthera Pharmaceuticals (ANTH) Set to Announce Earnings on MondayAnthera Pharmaceuticals (ANTH) Set to Announce Earnings on Monday
www.americanbankingnews.com - February 19 at 3:46 AM
Research Analysts Offer Predictions for Anthera Pharmaceuticals Incs Q1 2018 Earnings (ANTH)Research Analysts Offer Predictions for Anthera Pharmaceuticals Inc's Q1 2018 Earnings (ANTH)
www.americanbankingnews.com - February 19 at 3:16 AM
Research Analysts Set Expectations for Anthera Pharmaceuticals Incs FY2022 Earnings (ANTH)Research Analysts Set Expectations for Anthera Pharmaceuticals Inc's FY2022 Earnings (ANTH)
www.americanbankingnews.com - February 16 at 4:32 PM
FY2019 EPS Estimates for Anthera Pharmaceuticals Inc Raised by Analyst (ANTH)FY2019 EPS Estimates for Anthera Pharmaceuticals Inc Raised by Analyst (ANTH)
www.americanbankingnews.com - February 15 at 3:10 PM
Anthera Pharmaceuticals (ANTH) Rating Lowered to Hold at Zacks Investment ResearchAnthera Pharmaceuticals (ANTH) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 14 at 4:20 PM
Anthera Pharmaceuticals (ANTH) Stock Rating Upgraded by Zacks Investment ResearchAnthera Pharmaceuticals (ANTH) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 13 at 5:54 PM
Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey’s 4th Annual Orphan Drug DayAnthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey’s 4th Annual Orphan Drug Day
finance.yahoo.com - February 8 at 3:41 PM
Anthera Pharmaceuticals (ANTH) Rating Increased to Buy at Zacks Investment ResearchAnthera Pharmaceuticals (ANTH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - February 5 at 4:54 PM
Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of SollpuraAnthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura
finance.yahoo.com - February 5 at 9:34 AM
Anthera Pharmaceuticals (ANTH) Downgraded by Zacks Investment Research to "Hold"Anthera Pharmaceuticals (ANTH) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - February 2 at 5:36 PM
Will Gilead (GILD) Disappoint Investors in Q4 Earnings?Will Gilead (GILD) Disappoint Investors in Q4 Earnings?
finance.yahoo.com - February 1 at 9:32 AM
Can Molecular Diagnostics Arm Up Hologic (HOLX) Q1 Earnings?Can Molecular Diagnostics Arm Up Hologic (HOLX) Q1 Earnings?
finance.yahoo.com - January 29 at 3:43 PM
Anthera Pharma (ANTH) Receives Positive Nasdaq Listing DeterminationAnthera Pharma (ANTH) Receives Positive Nasdaq Listing Determination
www.streetinsider.com - January 26 at 9:08 AM
Anthera Receives Positive Nasdaq Listing DeterminationAnthera Receives Positive Nasdaq Listing Determination
finance.yahoo.com - January 26 at 9:08 AM
Today’s Research Reports on Trending Tickers: Anthera Pharmaceuticals and Cara TherapeuticsToday’s Research Reports on Trending Tickers: Anthera Pharmaceuticals and Cara Therapeutics
finance.yahoo.com - January 25 at 9:27 AM
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and BioverativThe Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
finance.yahoo.com - January 24 at 8:06 AM
Anthera Pharma (ANTH) Reports Positive Outcome of Second Interim Futility Analysis in Phase 3 RESULT Clinical Study of SollpuraAnthera Pharma (ANTH) Reports Positive Outcome of Second Interim Futility Analysis in Phase 3 RESULT Clinical Study of Sollpura
www.streetinsider.com - January 23 at 5:26 PM
Antheras Sollpura Strong on Positive Futility in Phase IIIAnthera's Sollpura Strong on Positive Futility in Phase III
www.zacks.com - January 23 at 5:26 PM
BRIEF-Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 Sollpura StudyBRIEF-Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 Sollpura Study
www.reuters.com - January 22 at 3:54 PM
Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this QuarterAnthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter
finance.yahoo.com - January 22 at 3:54 PM
BRIEF-683 Capital Management Reports 6.1 Pct Passive Stake In Anthera PharmaBRIEF-683 Capital Management Reports 6.1 Pct Passive Stake In Anthera Pharma
www.reuters.com - January 19 at 3:15 PM
Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering - GlobeNewswire (press release)Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering - GlobeNewswire (press release)
globenewswire.com - January 10 at 5:33 AM
Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement OfferingAnthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering
finance.yahoo.com - January 10 at 5:33 AM
Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders - GlobeNewswire (press release)Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders - GlobeNewswire (press release)
globenewswire.com - January 9 at 5:36 AM
Anthera Pharmaceuticals (ANTH) Raised to "Buy" at Zacks Investment ResearchAnthera Pharmaceuticals (ANTH) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 8 at 9:26 PM
Anthera Pharmaceuticals Announces Results of Special Meeting of StockholdersAnthera Pharmaceuticals Announces Results of Special Meeting of Stockholders
finance.yahoo.com - January 8 at 11:20 AM
Anthera Pharmaceuticals Announces Appointment of Patrick Murphy ... - GlobeNewswire (press release)Anthera Pharmaceuticals Announces Appointment of Patrick Murphy ... - GlobeNewswire (press release)
globenewswire.com - January 3 at 11:19 AM
Anthera Pharmaceuticals Announces Appointment of Patrick Murphy as Senior Vice President, ManufacturingAnthera Pharmaceuticals Announces Appointment of Patrick Murphy as Senior Vice President, Manufacturing
finance.yahoo.com - January 3 at 11:19 AM
Zacks: Brokerages Expect Anthera Pharmaceuticals Inc (ANTH) to Post -$0.82 Earnings Per ShareZacks: Brokerages Expect Anthera Pharmaceuticals Inc (ANTH) to Post -$0.82 Earnings Per Share
www.americanbankingnews.com - December 21 at 5:16 AM
Anthera Pharmaceuticals, Inc. (ANTH) Short Interest UpdateAnthera Pharmaceuticals, Inc. (ANTH) Short Interest Update
www.americanbankingnews.com - December 16 at 2:08 AM
Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical ... - GlobeNewswire (press release)Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical ... - GlobeNewswire (press release)
globenewswire.com - December 12 at 5:37 AM
Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of SollpuraAnthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura
finance.yahoo.com - December 11 at 3:15 PM
Anthera Pharmaceuticals, Inc. (ANTH) Given Average Rating of "Hold" by BrokeragesAnthera Pharmaceuticals, Inc. (ANTH) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 8 at 9:36 PM
Zacks: Analysts Expect Anthera Pharmaceuticals, Inc. (ANTH) Will Post Earnings of -$0.87 Per ShareZacks: Analysts Expect Anthera Pharmaceuticals, Inc. (ANTH) Will Post Earnings of -$0.87 Per Share
www.americanbankingnews.com - December 3 at 8:14 AM
Want To Invest In Anthera Pharmaceuticals Inc (ANTH)? Here’s How It Performed LatelyWant To Invest In Anthera Pharmaceuticals Inc (ANTH)? Here’s How It Performed Lately
finance.yahoo.com - November 30 at 5:32 AM
Anthera Pharmaceuticals: Buy The Dip - Seeking AlphaAnthera Pharmaceuticals: Buy The Dip - Seeking Alpha
seekingalpha.com - November 29 at 5:31 AM
Best Growth Stocks To BuyBest Growth Stocks To Buy
finance.yahoo.com - November 25 at 3:28 PM
Anthera Pharma (ANTH) Receives Nasdaq Listing Determination Notice, Plans AppealAnthera Pharma (ANTH) Receives Nasdaq Listing Determination Notice, Plans Appeal
www.streetinsider.com - November 18 at 1:41 AM
Jefferies Group Equities Analysts Lift Earnings Estimates for Anthera Pharmaceuticals, Inc. (ANTH)Jefferies Group Equities Analysts Lift Earnings Estimates for Anthera Pharmaceuticals, Inc. (ANTH)
www.americanbankingnews.com - November 17 at 9:44 PM
Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal - GlobeNewswire (press release)Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal - GlobeNewswire (press release)
globenewswire.com - November 17 at 8:41 PM
Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans AppealAnthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal
finance.yahoo.com - November 17 at 8:41 PM
Anthera Pharmaceuticals: Run Up Into Q1 Data - Seeking AlphaAnthera Pharmaceuticals: Run Up Into Q1 Data - Seeking Alpha
seekingalpha.com - November 16 at 11:14 AM
 Brokerages Expect Anthera Pharmaceuticals, Inc. (ANTH) Will Post Earnings of -$0.87 Per Share Brokerages Expect Anthera Pharmaceuticals, Inc. (ANTH) Will Post Earnings of -$0.87 Per Share
www.americanbankingnews.com - November 14 at 9:20 PM
BRIEF-Anthera Pharmaceuticals files for resale of up to 28.6 million shares of cos common stockBRIEF-Anthera Pharmaceuticals files for resale of up to 28.6 million shares of co's common stock
www.reuters.com - November 14 at 2:27 AM
Anthera Pharmaceuticals, Inc. (ANTH) Receives Average Rating of "Hold" from AnalystsAnthera Pharmaceuticals, Inc. (ANTH) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 13 at 9:34 PM

SEC Filings

Anthera Pharmaceuticals (NASDAQ:ANTH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Anthera Pharmaceuticals (NASDAQ:ANTH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Anthera Pharmaceuticals (NASDAQ ANTH) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.